Biofocus and CHDI Foundation have announced a five-year collaboration focused on discovering novel drugs for Huntingdon's disease.
Biofocus will perform the research and is eligible to receive USD41m (GBP26m) in research fees during the five-year collaboration.
The company will apply its full range of integrated drug discovery services for this programme.
Integrated biology and chemistry capabilities will be supported by Biofocus's expertise in complex primary neuronal assay development, high-content screening, fragment-based screening, computational chemistry, ADME/PK and protein crystallography.
The agreement continues and expands the collaborations started in August 2005.
